KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma

Oncogene

Volumn 30, Issue 28, 2011, Pages 3163-3173

  Jiffar, T ^a   Yilmaz, T ^a   Lee, J ^a   Hanna, E ^a   El Naggar, A ^b   Yu, D ^c   Myers, J N ^a   Kupferman, M E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Department of Molecular and Cellular Oncology 1515 Holcombe ^*  (United States)

Author keywords

chemotherapy resistance; cisplatin; head and neck squamous cell carcinoma; KiSS1; metastasis

Indexed keywords

CISPLATIN; GLUTATHIONE TRANSFERASE P1; MESSENGER RNA; METASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER SURVIVAL; CELL MIGRATION; CHEMOSENSITIVITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; EXPERIMENTAL MODEL; GENOME; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MALE; METASTASIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMS BIOLOGY; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE TRANSFERASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; NEOPLASM METASTASIS; PHENOTYPE; SUPPRESSION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

MURINAE; MUS;

EID: 79960348852     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.39     Document Type: Article

References (49)

1. Antoun G, Baylin SB, Ali-Osman F. (2000). DNA methyltransferase levels and altered CpG methylation in the total genome and in the GSTP1 gene in human glioma cells transfected with sense and antisense DNA methyltransferase cDNA. J Cell Biochem 77: 372-381. (Pubitemid 30230592)
2. Arai T, Yasuda Y, Takaya T, Hayakawa K, Toshima S, Shibuya C et al. (2000). Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer. Cancer Detect Prev 24: 252-257. (Pubitemid 30656733)
3. Bai F, Nakanishi Y, Kawasaki M, Takayama K, Yatsunami J, Pei XH et al. (1996). Immunohistochemical expression of glutathione Stransferase- Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer 78: 416-421. (Pubitemid 26250525)
4. Chanvorachote P, Nimmannit U, Stehlik C, Wang L, Jiang BH, Ongpipatanakul B et al. (2006). Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res 66: 6353-6360.
5. Cho S-G, Yi Z, Pang X, Yi T, Wang Y, Luo J et al. (2009). Kisspeptin- 10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res 69: 7062-7070.
6. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al. (2004). Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350: 1937-1944.
7. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR. (2003). Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 63: 8097-8102. (Pubitemid 37549452)
8. Di Pietro G, Magno LA, Rios-Santos F. (2010). Glutathione Stransferases: an overview in cancer research. Expert Opin Drug Metab Toxicol 6: 153-170.
9. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
10. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W et al. (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl JMed 349: 2091-2098. (Pubitemid 37464533)
11. Ganjavi H, Gee M, Narendran A, Freedman MH, Malkin D. (2005). Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 12: 397-406. (Pubitemid 40411199)
12. Goldberg SF, Miele ME, Hatta N, Takata M, Paquette-Straub C, Freedman LP et al. (2003). Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res 63: 432-440. (Pubitemid 36152504)
13. Hamaguchi K, Godwin AK, Yakushiji M, ODwyer PJ, Ozols RF, Hamilton TC. (1993). Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53: 5225-5232. (Pubitemid 23333392)
14. Hu H, Jiang C, Ip C, Rustum YM, La J. (2005). Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 11: 2379-2388. (Pubitemid 40490199)
15. Jiang Y, Berk M, Singh LS, Tan H, Yin L, Powell C et al. (2005). KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clin Exp Metast 22: 369-376. (Pubitemid 41609296)
16. Karin M, Lin A. (2002). NF-[kappa]B at the crossroads of life and death. Nat Immunol 3: 221-227.
17. Kelland L. (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584. (Pubitemid 47106628)
18. Khan K, Araki K, Wang D, Li G, Li X, Zhang J et al. (2010). Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 32: 381-391.
19. Kigawa J, Terakawa N. (2000). Adenovirus-mediated transfer of a p53 gene in ovarian cancer. Adv Exp Med Biol 465: 207-214. (Pubitemid 32193336)
20. Kim SJ, Kang HS, Jung SY, Min SY, Lee S, Kim SW et al. (2010). Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. J Mol Med 88: 1123-1131.
21. Kupferman ME, Jayakumar A, Zhou G, Xie T, Dakak-Yazici Y, Zhao M et al. (2009). Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 8: 117-127.
22. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T et al. (2010). TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29: 2047-2059.
23. Lee JH, Welch DR. (1997). Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 57: 2384-2387. (Pubitemid 27255895)
24. Li X, Stark GR. (2002). NF[kappa]B-dependent signaling pathways. Exp Hematol 30: 285-296.
25. Liang C-C, Park AY, Guan J-L. (2007). In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protocols 2: 329-333. (Pubitemid 47040047)
26. Liu L-Z, Zhou X-D, Qian G, Shi X, Fang J, Jiang B-H. (2007). AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70s6k1pathway. Cancer Res 67: 6325-6332. (Pubitemid 47037515)
27. Lo HW, Stephenson L, Cao X, Milas M, Pollock R, Ali-Osman F. (2008). Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. Mol Cancer Res 6: 843-850.
28. Marot D, Bieche I, Aumas C, Esselin S, Bouquet C, Vacher S et al. (2007). High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors. Endocr Relat Cancer 14: 691-702. (Pubitemid 350074058)
29. Masanek U, Stammler G, Volm M. (1997). Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anticancer Drugs 8: 189-198. (Pubitemid 27102234)
30. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR., Begum S et al. (2009). Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 15: 1645-1654.
31. Mitchell DC, Stafford LJ, Li D, Bar-Eli M, Liu M. (2007). Transcriptional regulation of KiSS-1 gene expression in metastatic melanoma by specificity protein-1 and its coactivator DRIP-130. Oncogene 26: 1739-1747. (Pubitemid 46426193)
32. Moffat GJ, McLaren AW, Wolf CR. (1996). Functional characterization of the transcription silencer element located within the human Pi class glutathione S-transferase promoter. J Biol Chem 271: 20740-20747. (Pubitemid 26281858)
33. Morceau F, Duvoix A, Delhalle S, Schnekenburger M, Dicato M, Diederich M. (2004). Regulation of glutathione S-transferase P1-1 gene expression by NF-kappaB in tumor necrosis factor alpha-treated K562 leukemia cells. Biochem Pharmacol 67: 1227-1238. (Pubitemid 38315088)
34. Nash KT, Phadke PA, Navenot J-M, Hurst DR, Accavitti-Loper MA, Sztul E et al. (2007). Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 99: 309-321. (Pubitemid 47078727)
35. Nash KT, Welch DR. (2006). The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci 11: 647-659. (Pubitemid 43258169)
36. Navenot J-M, Fujii N, Peiper SC. (2009a). Activation of Rho and Rho-associated kinase by GPR54 and KiSS1 metastasis suppressor gene product induces changes of cell morphology and contributes to apoptosis. Mol Pharmacol 75: 1300-1306.
37. Navenot J-M, Fujii N, Peiper SC. (2009b). KiSS1 metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to akt, tumor necrosis factor family ligand expression, and apoptosis. Mol Pharmacol 75: 1074-1083.
38. Niedner H, Christen R, Lin X, Kondo A, Howell SB. (2001). Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 60: 1153-1160. (Pubitemid 33144883)
39. ODonnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, OMalley B et al. (2005). Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 24: 1244-1251. (Pubitemid 40313925)
40. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K et al. (2001). Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 411: 613-617. (Pubitemid 32531412)
41. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. (2010). PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10: 293-301.
42. Soussi T. (2007). p53 alterations in human cancer: more questions than answers. Oncogene 26: 2145-2156. (Pubitemid 46536642)
43. Soussi T, Wiman KG. (2007). Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303-312. (Pubitemid 47539312)
44. Stewart DJ. (2007). Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12-31. (Pubitemid 46810280)
45. Sung-Gook C, Dali L, Lewis JS, Jian L, Melissa R-V, Ying W et al. (2009). KiSS1 suppresses TNFalpha-induced breast cancer cell invasion via an inhibition of RhoA-mediated NF-kappaB activation. J Cell Biochem 107: 1139-1149.
46. Welch DR, Chen P, Miele ME, McGary CT, Bower JM, Stanbridge EJ et al. (1994). Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 9: 255-262. (Pubitemid 24020957)
47. Yan C, Wang H, Boyd DD. (2001). KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balphainduced block of p65/p50 nuclear translocation. J Biol Chem 276: 1164-1172. (Pubitemid 32096543)
48. Yazlovitskaya EM, DeHaan RD, Persons DL. (2001). Prolonged wildtype p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 283: 732-737. (Pubitemid 32924639)
49. Yilmaz T, Jiffar T, de la Garza G, Lin H, MacIntyre T, Brown JL et al. (2010). Therapeutic targeting of Trk suppresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol Ther 10: 644-653.